All conditions

Thyroid Cancer

Plain English clinical trial information, updated daily from ClinicalTrials.gov and public government registries. Not medical advice.

1124
Trials on record
214
Recruiting now
5
Australian sites
12
Phase 3 trials
3
PBS medicines
How these figures are counted
  • Trials on record is every trial tagged to this condition at any stage, except those withdrawn before starting or terminated early. Most are completed rather than ongoing, so this is a measure of research history, not of current activity. It is also smaller than the sitewide "trials tracked" figure, which does include withdrawn and terminated trials.
  • Recruiting now counts only trials whose registry status is "Recruiting". Trials listed as not yet recruiting or enrolling by invitation are excluded, so this understates how many may open to new participants soon.
  • Australian sites counts trials counted under "Recruiting now" that list at least one Australian site. A site being listed does not mean it is currently enrolling, and Australian trials registered only on ANZCTR are not counted yet, so this understates local availability.
  • Phase 3 trials counts trials counted under "Recruiting now" that are at Phase 3.

Find recruiting trials for Thyroid Cancer →

Get alerts when Thyroid Cancer trials change ↗

Voxsanity currently covers 103 conditions. We are expanding coverage regularly.

Understanding Thyroid Cancer

Thyroid cancer is a condition where abnormal cells grow in the thyroid gland, a small butterfly-shaped gland sitting at the front of your neck. The thyroid plays an important role in producing hormones that help control your metabolism, heart rate, and other body functions. There are several different types of thyroid cancer, with the most common being papillary and follicular thyroid cancer. These types tend to grow slowly and are often found early. Less common types, such as medullary and anaplastic thyroid cancer, can behave differently and may require different approaches to care.

Thyroid cancer is one of the more commonly diagnosed cancers in Australia. Around 3,500 Australians are diagnosed each year, and it is more frequently diagnosed in women than men, though it can affect anyone at any age. In many cases, it is found when a person or their doctor notices a lump or swelling in the neck, or it may be picked up during a scan done for another reason. Most people diagnosed with the common forms of thyroid cancer have very positive outcomes, particularly when it is found early.

Treatment varies depending on the type and stage of the cancer, as well as the individual person's circumstances. Surgery to remove part or all of the thyroid gland is a common approach. Some people also receive radioactive iodine therapy after surgery to help target any remaining thyroid cells. Thyroid hormone medication is often prescribed following surgery. A team of specialists, which may include surgeons, endocrinologists, and oncologists, will typically work together to discuss the most suitable options for each person. Your medical team is the best source of guidance for your specific situation.

This overview is an AI generated summary written from public medical sources and checked on a sample basis. It is general information, not medical advice or a diagnosis. Always speak with your doctor about your situation. How we use AI

Can you access treatment for Thyroid Cancer in Australia right now? Here's what's publicly known.

Information on this site does not constitute medical advice. Data is sourced from publicly available government registries. Always consult your doctor before making any health decisions. Trial status should be verified directly with the trial site.

Updated regularly from public government registries

PBS-subsidised medicines for Thyroid Cancer

3 medicines listed on the PBS for Thyroid Cancer. Filter by authority type, or open the full table below.

What the authority types mean Unrestricted: no clinical criteria; a doctor can prescribe it on the PBS for any appropriate use. Restricted benefit: subsidised only for the specific conditions or uses set out by the PBS. Streamlined authority: restricted, but the doctor does not need prior approval; they record a streamlined authority code confirming you meet the criteria. Authority required: restricted, and the doctor must get prior approval from Services Australia (by phone or online) before it is subsidised. Source: Pharmaceutical Benefits Scheme (pbs.gov.au).
Full PBS medicines table 3 listed

These medicines are listed on the Pharmaceutical Benefits Scheme (PBS) for the specific indications shown. A listing does not mean a medicine is right for you; your doctor decides what is appropriate. Prices shown are the PBS-determined dispensed price. Most patients pay only the standard co-payment, up to AU$25.00 per script (general) or AU$7.70 (concession or Safety Net) in 2026, with the Australian Government subsidising the rest.

Medicine Brand(s) Listed for
Cabozantinib Cabometyx differentiated thyroid cancer Locally advanced or metastatic AU$9310 Streamlined authority
Lenvatinib Lenvima differentiated thyroid cancer Locally advanced or metastatic AU$2000 Streamlined authority
Liothyronine Tertroxin Thyroid cancer AU$41.19 Streamlined authority

Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.

Research pipeline

Where trials for Thyroid Cancer currently sit in the development pipeline. The funnel shape shows how few drugs reach later phases in general; the counts are this condition's actual trial numbers.

Phase success rates are industry-wide historical averages, not predictions for specific trials. Learn how trials work →

Most active research sponsors

Organisations with the most recruiting trials for Thyroid Cancer.

View sponsor profile
View sponsor profile
View sponsor profile
View sponsor profile
View sponsor profile

Where trials are running

Clinical trial sites for Thyroid Cancer by country. Australia is highlighted.

Showing the top 10 of 40 countries with trial sites.

Clinical trials for Thyroid Cancer

Showing 222 of 222 trials

The plain English eligibility text on each trial below is an AI generated summary of the official criteria, checked on a sample basis. How we use AI

🇦🇺 NCT01896479 · Exelixis Phase 4 · 14 countries Active, Not Recruiting
Active, Not Recruiting Phase 4 Est. completion 15 July 2020
🇦🇺 AU🇨🇦 CA🇭🇷 HR🇫🇷 FR🇭🇺 HU🇮🇱 IL🇮🇹 IT🇳🇱 NL +6 more

**Who might be able to join this trial:** - You have been diagnosed with medullary thyroid cancer (MTC), confirmed by a lab test on a tissue sample. - You have been tested (or are willing to be tested) for a specific genetic change called a RET mutation, using a tumor sample. - You have cancer that has spread to other...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
🇦🇺 NCT03690388 · Exelixis Phase 3 · 25 countries Active, Not Recruiting
Active, Not Recruiting Phase 3 Est. completion 19 August 2020
🇦🇷 AR🇦🇺 AU🇦🇹 AT🇧🇪 BE🇧🇷 BR🇨🇦 CA🇭🇷 HR🇨🇿 CZ +17 more

**Who might be able to join this trial:** - You have been diagnosed with a type of thyroid cancer called "differentiated thyroid cancer," confirmed by a lab test on a tissue or cell sample. - Your cancer can be measured on a scan according to a standard set of medical guidelines. - You have already been treated with r...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT04211337 · Loxo Oncology, Inc. Phase 3 · 20 countries Active, Not Recruiting
Active, Not Recruiting Phase 3 Est. completion 22 May 2023
🇦🇺 AU🇧🇪 BE🇧🇷 BR🇨🇦 CA🇨🇳 CN🇨🇿 CZ🇫🇷 FR🇩🇪 DE +12 more

Who might be able to join this trial: - You are at least 18 years old (or as young as 12 in some locations if local health authorities allow it). - You have been diagnosed with a type of thyroid cancer called medullary thyroid cancer (MTC) that cannot be removed by surgery and has either spread or is advanced, and you...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT01321554 · Eisai Inc. Phase 3 · 23 countries Completed
Completed Phase 3 Est. completion 15 November 2013
🇦🇷 AR🇦🇺 AU🇦🇹 AT🇧🇪 BE🇧🇷 BR🇨🇦 CA🇨🇱 CL🇨🇿 CZ +15 more

Who might be able to join this trial: - You have been diagnosed with either papillary thyroid cancer or follicular thyroid cancer, confirmed by a lab test on a tissue or cell sample. - Your cancer can be measured on a scan, as confirmed by an independent radiology review. - Your cancer no longer responds to radioactive...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT01502410 · National Cancer Institute (NCI) Phase 2 · 3 countries Completed
Completed Phase 2 Est. completion 1 June 2014
🇦🇺 AU🇨🇦 CA🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed (either at first diagnosis or at relapse) with one of these cancers: rhabdomyosarcoma (a muscle tissue cancer), Wilms tumor (a kidney cancer), hepatocellular carcinoma (a liver cancer), or papillary thyroid carcinoma (a type of thyroid cancer)...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT02702388 · Eisai Inc. Phase 2 · 16 countries Completed
Completed Phase 2 Est. completion 12 December 2019
🇦🇺 AU🇧🇪 BE🇨🇦 CA🇩🇰 DK🇫🇷 FR🇩🇪 DE🇮🇱 IL🇮🇹 IT +8 more

**Who might be able to join this trial:** - People who have been confirmed by tissue or cell testing to have a specific type of differentiated thyroid cancer (DTC), including papillary thyroid cancer (and its variants) or follicular thyroid cancer (and its variants). - People who have at least one tumour that is large...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT03093116 · Turning Point Therapeutics, Inc. Phase 2 · 19 countries Recruiting
Recruiting Phase 2 Est. completion 29 February 2028
🇦🇺 AU🇧🇪 BE🇨🇦 CA🇨🇳 CN🇩🇰 DK🇫🇷 FR🇩🇪 DE Hong Kong +11 more

**Who might be able to join this trial:** - You have been diagnosed with an advanced or spreading solid tumor (including brain tumors) that has been confirmed by lab testing to have a specific gene change in ALK, ROS1, NTRK1, NTRK2, or NTRK3 - You are generally able to carry out daily activities with little to no limi...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT03175224 · Apollomics Inc. Phase 2 · 11 countries Recruiting
Recruiting Phase 2 Est. completion 30 March 2026
🇦🇺 AU🇨🇦 CA🇫🇷 FR🇭🇺 HU🇮🇹 IT🇷🇺 RU🇸🇬 SG🇪🇸 ES +3 more

**Who might be able to join this trial:** - Adults aged 18 or older. - People diagnosed with a type of lung cancer called non-small cell lung cancer (NSCLC) that has a specific gene change called an "Exon 14 skipping mutation," where the cancer cannot be surgically removed or has spread, and who have not yet received...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT05024929 · Children's Hospital of Philadelphia Not Applicable · 2 countries Recruiting
Recruiting Not Applicable Est. completion 1 February 2031
🇦🇺 AU🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with differentiated thyroid cancer, confirmed by a tissue sample analysis. - Your cancer has been tested in a certified lab and found to have a specific genetic change, such as an NTRK fusion, RET fusion, ALK fusion, BRAF V600 mutation, BRAF fusion, o...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
🇦🇺 NCT05503797 · Fore Biotherapeutics Phase 2 · 12 countries Recruiting
Recruiting Phase 2 Est. completion 31 December 2027
🇦🇺 AU🇨🇦 CA🇫🇷 FR🇩🇪 DE🇮🇹 IT🇳🇱 NL🇳🇴 NO🇰🇷 KR +4 more

**Who might be able to join this trial:** This trial has four groups (called subprotocols A, B, C, and D). The criteria below are organised by group. **Subprotocol A (Solid tumors or brain tumors with a BRAF gene fusion):** - People aged 8 or older who weigh at least 25 kg (about 55 lbs), of any sex - People who have...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT05538130 · Pfizer Phase 1 · 7 countries Recruiting
Recruiting Phase 1 Est. completion 2 August 2027
🇦🇺 AU🇧🇷 BR🇨🇦 CA🇨🇳 CN🇮🇱 IL🇯🇵 JP🇺🇸 US

Who might be able to join this trial: - People who have been diagnosed with an advanced or spreading solid tumour (not including colorectal/bowel cancer) - People whose disease can be measured using standard imaging criteria (known as RECIST version 1.1) - People whose tumour has a specific genetic change called a BRAF...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT02657369 · Eisai Inc. Phase 2 · 5 countries Terminated
Terminated Phase 2 Est. completion 26 September 2018
🇦🇺 AU🇫🇷 FR🇮🇹 IT🇬🇧 GB🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with Anaplastic Thyroid Cancer (ATC), confirmed by a tissue biopsy (not just a fine needle aspiration alone). - A central laboratory review of your cancer diagnosis is required for the study, though it does not have to be completed before you start tr...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04284774 · National Cancer Institute (NCI) Phase 2 · 2 countries Active, Not Recruiting
Active, Not Recruiting Phase 2 Est. completion 31 March 2024
Puerto Rico🇺🇸 US

**Who might be able to join this trial:** - You must have already enrolled in a related study (called APEC1621SC / NCT03155620) and been matched to this treatment based on a specific genetic change found in your cancer. - You must be at least 12 months old and no older than 21 years old when joining the study. - Your...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT00001160 · National Institute of Diabetes and Digestive and Kidney Diseases (NIDD... Not Applicable · 1 country Recruiting
Recruiting Not Applicable
🇺🇸 US

Who might be able to join this trial: - You are a male or female, either an adult or a child aged 6 months or older - You have known or suspected thyroid nodules (lumps on the thyroid gland) and/or thyroid cancer - You are a family member of someone with a genetic risk of developing thyroid cancer Who may not be able...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT01005654 · National Cancer Institute (NCI) Not Applicable · 1 country Recruiting
Recruiting Not Applicable
🇺🇸 US

**Who might be able to join this trial:** - People who have a suspected or confirmed tumour of an endocrine gland — such as the thyroid, parathyroid, adrenal glands, pancreas, or related areas — based on imaging, blood/urine tests, or tissue samples already taken. - People who have a pre-cancerous or potentially cance...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT01109420 · National Institute of Diabetes and Digestive and Kidney Diseases (NIDD... Not Applicable · 1 country Recruiting
Recruiting Not Applicable
🇺🇸 US

**Who might be able to join this trial:** - Adults or children aged 7 years and older (both male and female) may be eligible - Someone who has not been diagnosed with thyroid cancer themselves, but has 2 close family members (such as parents, siblings, or children) who have or have had a specific type of thyroid cancer...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT01247597 · National Cancer Institute (NCI) Not Applicable · 1 country Recruiting
Recruiting Not Applicable
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with a type of tumor confirmed by a tissue sample (biopsy) called PPB (pleuropulmonary blastoma) and/or another tumor linked to a gene called DICER1 - You have a known or suspected change (variant) in the DICER1 gene - You have been diagnosed with one...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT01660984 · National Cancer Institute (NCI) Not Applicable · 1 country Recruiting
Recruiting Not Applicable
🇺🇸 US

**Who might be able to join this trial:** *(For patients)* - You have been diagnosed with medullary thyroid cancer (a type of thyroid cancer), confirmed by laboratory testing, OR you have been diagnosed with a genetic condition called MEN2A or MEN2B (with or without thyroid cancer). - You are able to travel to the NIH...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT02609685 · Cedars-Sinai Medical Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2030
🇺🇸 US

Who might be able to join this trial: - Your thyroid nodule has been tested and found to be either highly suspicious or confirmed as a type of thyroid cancer called papillary thyroid carcinoma, or it has a specific gene change called a BRAF mutation (confirm with trial site for exact biopsy category) - Your thyroid nod...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT02747888 · Dana-Farber Cancer Institute Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 March 2029
🇺🇸 US

**Who might be able to join this trial:** - Children and teenagers (under 18) who currently have, or have previously had, a known or suspected thyroid cancer or thyroid nodule(s). - Adults who currently have, or have previously had, a known or suspected thyroid cancer or thyroid nodule(s), if they come from a family w...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT02869620 · Institut Paoli-Calmettes Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2030
🇫🇷 FR

Who might be able to join this trial: - You have been diagnosed with thyroid cancer Who may not be able to join: - There are no stated exclusion criteria for this trial (confirm with trial site) Important: Always verify eligibility with the trial site directly before applying.

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03093909 · M.D. Anderson Cancer Center Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 30 November 2027
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with a solid tumor that has spread to the lungs, and there is no known treatment that can cure your cancer or has been proven to extend your life with a good quality of life. - You are willing to follow the study plan and take part in required safety...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT03099356 · University of Michigan Rogel Cancer Center Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 December 2026
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with a type of thyroid cancer called differentiated thyroid cancer (confirmed by a lab test), with or without spread to other parts of the body, and it cannot be fully cured — or you have chosen to decline curative treatment - Your cancer can be measu...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT03160274 · The University of Texas Health Science Center at San Antonio Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2030
🇺🇸 US

Who might be able to join this trial: - You have been diagnosed with a pheochromocytoma (a type of adrenal gland tumor) and/or a paraganglioma (a related tumor that can grow in other parts of the body) - A family member of yours has been diagnosed with a pheochromocytoma and/or a paraganglioma - You have been diagnosed...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03382158 · Children's Hospitals and Clinics of Minnesota Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 6 December 2030
🇺🇸 US

Who might be able to join this trial: - People who have been diagnosed with, or are suspected to have, a type of lung tumour called pleuropulmonary blastoma (PPB) or a related chest tumour - People who have been diagnosed with, or are suspected to have, certain tumours affecting the reproductive organs, including Serto...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03410394 · Central Hospital, Nancy, France Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2030
🇫🇷 FR

Who might be able to join this trial: - People who are having surgery for an endocrine (hormone-related) tumor at the University Nancy Brabois Hospital Who may not be able to join: - People who are unable to understand and receive clear information about the trial - People who are not willing to sign the consent form...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03483337 · Memorial Sloan Kettering Cancer Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 March 2027
🇺🇸 US

**Who might be able to join this trial:** - You must be 18 years of age or older - (Group 1) You have a suspicious spot in the head and neck area that doctors think may be a spread of cancer or a return of cancer - (Group 2) You have been confirmed by biopsy to have head and neck cancer or thyroid cancer (certain types...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03517579 · Johns Hopkins University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 15 October 2027
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with Graves' disease (an overactive thyroid condition) that has been confirmed by blood tests (Group I). - You are able to understand English and follow instructions (Group I). - You have been diagnosed with differentiated thyroid cancer that is consi...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03647358 · Memorial Sloan Kettering Cancer Center Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 August 2027
🇺🇸 US

**Who might be able to join this trial:** - You are an adult (18 or older) who has been diagnosed with thyroid cancer, confirmed by a tissue sample test. - You have had surgery to remove your entire thyroid gland. - You have thyroid cancer that has spread (or may have spread) to other parts of the body, or you are taki...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT03676348 · Oslo University Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 April 2023
🇳🇴 NO

Who might be able to join this trial: - People who are scheduled to have part or all of their thyroid gland removed at the ENT Department of Oslo University Hospital - People who have a growth in the thyroid gland where test results (from a fine needle biopsy) or other clinical signs suggest cancer may be present - Peo...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03676647 · City of Hope Medical Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 25 September 2028
🇺🇸 US

Who might be able to join this trial: - You are having a fine needle aspiration (FNA) procedure to help diagnose a thyroid nodule (a lump on the thyroid gland). - People of any race or ethnicity are welcome to take part. - After your FNA procedure, the results came back "indeterminate" — meaning the results were unclea...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03765333 · Grupo Espanol de Tumores Neuroendocrinos Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2025
🇪🇸 ES

Who might be able to join this trial: - You are 18 years old or older and have been diagnosed with differentiated, medullary, or anaplastic thyroid cancer, confirmed by a tissue sample test (biopsy). - You are willing to take part and are able to understand the study information and sign a consent form agreeing to part...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03841617 · National Institute of Diabetes and Digestive and Kidney Diseases (NIDD... Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 November 2035
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with thyroid cancer, confirmed by a pathology report reviewed at the National Institutes of Health. - People who have had their entire thyroid removed (and possibly nearby lymph nodes), and whose cancer has come back or spread — either confirme...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT03892993 · M.D. Anderson Cancer Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 August 2028
🇺🇸 US

**Who might be able to join this trial:** - You are 18 years old or older - You fall into one of these groups: you are a patient or survivor who has been diagnosed with medullary thyroid carcinoma (a type of thyroid cancer) by a doctor or through a medical registry; OR you are a family member or caregiver of such a pat...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03975231 · City of Hope Medical Center Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 5 October 2027
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with anaplastic thyroid cancer, confirmed by a tissue or cell sample (a result described as "consistent with" this diagnosis, alongside a thyroid mass, is also acceptable). - Your tumor has been tested and found to have a specific genetic change calle...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04104529 · Institut du Cancer de Montpellier - Val d'Aurelle Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 October 2026
🇫🇷 FR

**Who might be able to join this trial:** - You are 18 years old or older - You are being treated in a Nuclear Medicine Department using a type of treatment called metabolic radiotherapy - You are being treated for one of the following conditions: thyroid cancer, a neuroendocrine tumor, or prostate cancer - You have ag...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04119024 · Anusha Kalbasi Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 October 2026
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with a cancer that cannot be cured with surgery, specifically: advanced melanoma (stage IIIC or IV, including cases where cancer has spread to the brain), or another type of solid tumor (not in the brain) that has stopped responding to all standard tr...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04216732 · M.D. Anderson Cancer Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2026
🇺🇸 US

Who might be able to join this trial: - People who have been diagnosed with medullary thyroid cancer (a specific type of thyroid cancer, sometimes called MTC) may be eligible for parts of this trial (Aims 1 and 2). - People who are already registered in the Medullary Thyroid Cancer Registry (a database that tracks peop...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04290663 · Centre Francois Baclesse Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 February 2031
🇫🇷 FR

**Who might be able to join this trial:** - You have been diagnosed with a specific type of thyroid cancer called differentiated thyroid cancer (either papillary, follicular, or Hürthle cell type) that is considered "intermediate risk," based on how far it has spread and its characteristics - Your cancer does not have...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04589624 · M.D. Anderson Cancer Center Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 31 May 2027
🇺🇸 US

Who might be able to join this trial: - You are willing and able to give your consent to take part in the study - You have been told that this study is investigational (still being researched) - You have been diagnosed with thyroid cancer or another type of cancer in the head or neck area, and are planning to receive t...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04615988 · Icahn School of Medicine at Mount Sinai Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2028
🇺🇸 US

Who might be able to join this trial: - People who have a cancer that their oncologist plans to treat next with a type of immunotherapy drug that targets PD-1 or PD-L1, where that drug is the only immunotherapy being used (a separate group of 25 people also needs to be planned for treatment with both an anti-PD-1/PD-L1...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04666103 · Wuhan University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2021
🇨🇳 CN

Who might be able to join this trial: - People who have been diagnosed with thyroid cancer on one side of the thyroid gland, and have a non-cancerous nodule on the other side, confirmed by a pre-surgery needle biopsy guided by ultrasound. - People whose non-cancerous nodule on the other side measures 20mm or smaller an...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04693377 · M.D. Anderson Cancer Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 April 2027
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with cancer that has spread to the bones (bone metastases), confirmed by a scan. - Your cancer is one of the following types: kidney cancer (renal cell carcinoma), bladder/urinary tract cancer (urothelial carcinoma), prostate cancer that no longer res...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04742608 · Jonsson Comprehensive Cancer Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 9 June 2025
🇺🇸 US

Who might be able to join this trial: - You are 18 years of age or older - You have agreed to have thyroid surgery for either thyroid cancer or a thyroid nodule that needs further investigation to determine if it is cancerous Who may not be able to join: - You currently have another type of cancer at the same time as...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04892303 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 December 2027
🇺🇸 US

**Who might be able to join this trial:** - People aged 18 to 85 years old. - People who have been diagnosed with a specific type of thyroid cancer (called papillary or follicular thyroid carcinoma, together known as differentiated thyroid carcinoma), confirmed through a tissue sample, that has not fully responded to...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04916990 · University of Colorado, Denver Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2027
🇺🇸 US

**Who might be able to join this trial:** - People aged 18 or older - People who speak English or Spanish - People who are willing to follow all study procedures and take part for the full duration of the study - People who are receiving cancer treatment at one of these specific hospitals or cancer centers: UCHealth A...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04927416 · National Institute of Diabetes and Digestive and Kidney Diseases (NIDD... Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 November 2030
🇺🇸 US

**Who might be able to join this trial:** - You must be male or female and 18 years of age or older. - If you have differentiated thyroid cancer (DTC) or Hürthle cell thyroid cancer (HTC): your cancer must have spread locally or to other parts of the body, AND either not respond to radioactive iodine (RAI) treatment b...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05088187 · Karolinska University Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 November 2023
🇸🇪 SE

Who might be able to join this trial: - Adults over 18 years old who have been recommended for surgery due to a thyroid nodule that has been classified at a certain risk level (Bethesda category IV, V, or VI) - People who can read and understand the Swedish language - People who have access to a desktop computer or lap...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05172921 · Icahn School of Medicine at Mount Sinai Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2030
🇺🇸 US

**Who might be able to join this trial:** - Your thyroid biopsy (fine needle aspiration) result falls into one of these categories: Bethesda III, IV, V, or VI (meaning the result was uncertain, suspicious, or showed abnormal cells) — if your result turns out to be non-cancerous after surgery, your data and samples may...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05189314 · Columbia University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 August 2027
🇺🇸 US

Who might be able to join this trial: - You are 18 years old or older - You have been diagnosed with a non-cancerous (benign) thyroid nodule Who may not be able to join: - You have an irregular heartbeat or a heart rhythm condition - You are pregnant Important: Always verify eligibility with the trial site directly b...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05229341 · City of Hope Medical Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 22 October 2026
🇺🇸 US

Who might be able to join this trial: - People aged 18 or older who are having a needle biopsy to check a thyroid nodule - People who are able to make their own decisions about participating - People of any gender, race, or ethnicity - People who have given their written consent for their tissue samples and medical inf...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05264857 · Stony Brook University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 September 2027
🇺🇸 US

Who might be able to join this trial: - Your thyroid tissue sample (biopsy) has come back showing cells that are either uncertain or potentially cancerous (known as Bethesda category III, IV, V, or VI) (confirm with trial site) - The thyroid nodule (lump) being examined is 2 centimetres or smaller in size Who may not...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05316922 · Fondazione IRCCS Istituto Nazionale dei Tumori, Milano Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 30 September 2029
🇮🇹 IT

Who might be able to join this trial: - You have been diagnosed with medulloblastoma (a type of brain tumour) or Hodgkin/non-Hodgkin Lymphoma (types of blood cancer), and your radiation therapy treatment has not yet started, where the radiation would include the area around your thyroid gland (a gland in your neck) - Y...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05334069 · Alliance for Clinical Trials in Oncology Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 January 2027
🇺🇸 US

Who might be able to join this trial: - You have been diagnosed with an invasive cancer that has been confirmed by a tissue sample (biopsy), or you are strongly suspected of having certain cancers (ovarian, pancreatic, kidney, or melanoma) with a confirmed diagnosis expected within 28 days - Your cancer is one of the f...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05355701 · Pfizer Phase 1 · 3 countries Recruiting
Recruiting Phase 1 Est. completion 23 April 2028
🇨🇦 CA🇮🇱 IL🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with an advanced or metastatic solid tumour, including primary brain tumours (tumours that started in the brain). - People whose tumour has a specific gene change called a BRAF alteration (either a V600 type or a non-V600 Class II/Class III typ...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05366881 · Adela, Inc Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 March 2026
🇺🇸 US

**Who might be able to join this trial:** *For people recently diagnosed with cancer ("cases"):* - You have been newly diagnosed with cancer within the last 120 days, or have had a cancer come back after being cancer-free for more than 5 years, and your cancer is one of these types: Brain, Breast, Bladder, Cervical, C...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05451602 · Sunshine Lake Pharma Co., Ltd. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 December 2026
🇨🇳 CN

**Who might be able to join this trial:** - (Phase 1 only) You have been diagnosed with a solid tumor cancer that has spread and cannot be removed by surgery. - (Phase 2 only) Your tumor has been tested and found to have a specific gene change called a RET rearrangement, fusion, or certain RET mutation. - You are able...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05510934 · Nova Scotia Health Authority Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 September 2025
🇨🇦 CA

Who might be able to join this trial: - Adults (over 18 years old) who are being seen at the Halifax Interdisciplinary Thyroid Oncology Clinic (ITOC) - People with Stage 1 differentiated thyroid cancer (a specific type and stage of thyroid cancer) where there are no signs of cancer on scans or blood tests, including a...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05575440 · Mayo Clinic Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 May 2028
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with papillary or follicular thyroid cancer, confirmed by a tissue biopsy - Your doctor has recommended you have a standard total body iodine scan using a radioactive substance called I-123 - You are willing to have an additional type of scan called an...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05599139 · University Medical Center Groningen Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 March 2026
🇳🇱 NL

**Who might be able to join this trial:** - You are a man or woman aged 18 or older who has been diagnosed with differentiated thyroid cancer (a type of thyroid cancer) - You are required to follow a low-iodine diet before your radioactive iodine treatment, as part of standard thyroid cancer care in the Netherlands - Y...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05604963 · University College, London Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 July 2028
🇬🇧 GB

**Who might be able to join this trial:** **If you have already had your whole thyroid removed (Group 1):** - You are aged 16 or older - You have been diagnosed with papillary thyroid cancer (PTC) where the tumour was between 1cm and 4cm, regardless of genetic markers found in the tumour - Your surgeon was able to re...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05607407 · Case Comprehensive Cancer Center Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 September 2026
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with a high-grade brain tumor (WHO grade 4 glioma) that has been confirmed by lab testing, and surgery to remove part or all of the tumor is already planned. - You have never been treated with a drug called methimazole for this brain tumor. - You are...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05668962 · Massachusetts General Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 March 2025
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with a specific type of thyroid cancer (follicular-derived, non-anaplastic) that has spread or cannot be removed by surgery, and whose cancer has a specific genetic change called a RET gene fusion, confirmed by an accredited laboratory. - Peopl...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05726981 · Assistance Publique - Hôpitaux de Paris Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 April 2026
🇫🇷 FR

**Who might be able to join this trial:** - You are over 18 years old - You have a non-cancerous (benign) thyroid nodule that was treated with a heat-based procedure called radiofrequency thermoablation approximately 24 to 48 months ago (between 2 and 4 years ago), regardless of whether the nodule has stayed the same s...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05733013 · Memorial Sloan Kettering Cancer Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 7 February 2028
🇺🇸 US

Who might be able to join this trial: - You are 18 years old or older at the time of giving consent. - You have been diagnosed with thyroid cancer that no longer responds to radioactive iodine treatment, or is unlikely to respond to it. - You are scheduled to receive "redifferentiation" drugs (medicines that may help t...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05752604 · Istituto Auxologico Italiano Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 8 March 2032
🇮🇹 IT

Who might be able to join this trial: - You have been diagnosed with thyroid cancer Who may not be able to join: - You are not able to sign a consent form agreeing to take part in the trial Important: Always verify eligibility with the trial site directly before applying.

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05766098 · Istituto Auxologico Italiano Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 October 2027
🇮🇹 IT

Who might be able to join this trial: - You have been diagnosed with papillary thyroid cancer - Your tumor tissue is available and can be used for genetic testing Who may not be able to join: - You have not given your consent to take part in the study - You were unable to be contacted or followed up with during the st...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05783323 · Children's Hospital of Philadelphia Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 October 2026
🇺🇸 US

Who might be able to join this trial: - People aged 1 year or older - People who have been diagnosed with differentiated thyroid cancer through a tissue biopsy, have had their thyroid surgically removed, and have received appropriate local treatment (such as removal of affected lymph nodes in the neck) for cancer that...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05786924 · Institut de Recherches Internationales Servier Phase 2 · 5 countries Recruiting
Recruiting Phase 2 Est. completion 1 June 2028
🇩🇰 DK Hong Kong🇯🇵 JP🇬🇧 GB🇺🇸 US

**Who might be able to join this trial:** - Doctors believe you are expected to live at least 12 weeks or more - You have been diagnosed (confirmed by a lab test on tissue or cell samples) with an advanced, locally spread, or metastatic (spread to other parts of the body) solid tumour that cannot be surgically removed...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05789667 · Regina Elena Cancer Institute Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2024
🇮🇹 IT

"Who might be able to join this trial: - People diagnosed with a type of thyroid cancer called differentiated thyroid cancer (DTC) that no longer responds to radioactive iodine treatment, and who are currently being treated with a medication called lenvatinib - People who have signed a written consent form agreeing to...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05830500 · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 1 June 2027
🇨🇳 CN

**Who might be able to join this trial:** - You are willing to take part voluntarily, have signed a consent form, and are able to follow the study requirements - You are 18 years of age or older, are reasonably physically active in daily life (as rated by your doctor on a standard scale), and are expected to live for...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT05837260 · Royal Marsden NHS Foundation Trust Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 7 February 2027
🇬🇧 GB

**Who might be able to join this trial:** - People aged 18 years or older - People diagnosed with radioiodine-refractory differentiated thyroid cancer (a type of thyroid cancer that no longer responds to radioiodine treatment) who are currently being monitored (Cohort 1) - People newly diagnosed with medullary thyroid...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05852223 · Istituti Clinici Scientifici Maugeri SpA Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 November 2026
🇮🇹 IT

**Who might be able to join this trial:** - Adults aged 18 or older who have been diagnosed with differentiated thyroid cancer (confirmed by laboratory tissue testing) and are scheduled for surgery, with no previous treatment for this cancer - People whose cancer carries a greater than 20% chance of coming back or per...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05903196 · Northwell Health Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2025
🇺🇸 US

**Who might be able to join this trial:** - You are able to understand and agree to take part in the study on your own - You are willing to follow all study procedures and can be available for the full length of the study - You are 18 years of age or older - You identify as LatinX - You have a thyroid nodule (a lump in...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05962892 · Beijing Friendship Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 28 February 2028
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 or older - People who have given their informed consent to take part - People whose ultrasound scan shows a single cancerous thyroid nodule that is no larger than 1cm at its widest point, and is at least 2mm away from the outer layer of the thyroid - People wit...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05989425 · Fudan University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 4 August 2026
🇨🇳 CN

**Who might be able to join this trial:** - You have been diagnosed with locally advanced or metastatic thyroid cancer (specific types include papillary, follicular, poorly differentiated, or particularly differentiated thyroid cancer), confirmed by a tissue or cell sample test - Your cancer is considered locally adva...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05994365 · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 August 2027
🇨🇳 CN

**Who might be able to join this trial:** - You are willing to take part, have signed a consent form, and are able to follow the study requirements - You are between 18 and 70 years old, are generally in good physical condition (able to carry out daily activities), and are expected to live for more than 6 months - You...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05999630 · Vanderbilt University Medical Center Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 31 December 2027
🇺🇸 US

Who might be able to join this trial: - People who are receiving radioiodine (radioactive iodine) treatment for thyroid cancer - People whose radioiodine treatment dose is 150 mCi or higher - People who are 18 years of age or older Who may not be able to join: - People who use any eye drops other than plain artificial...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06007924 · Memorial Sloan Kettering Cancer Center Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 16 August 2027
🇺🇸 US

**Who might be able to join this trial:** - People aged 18 or older who have a confirmed diagnosis of either differentiated thyroid cancer (such as papillary, follicular, Hürthle cell, or poorly differentiated thyroid cancer) for Cohort A, or anaplastic thyroid cancer for Cohort B. - People whose thyroid tumour has be...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06079333 · Leiden University Medical Center Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 January 2027
🇳🇱 NL

**Who might be able to join this trial:** - People who have given their written consent to participate - People aged 18 years or older - People whose general health and ability to carry out daily activities is rated at a high level (WHO Performance Status 0 or 1, meaning fully active or able to do light work) - People...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06082180 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 30 June 2025
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 to 70 years old who are reasonably active and able to carry out daily activities (as measured by a standard health scale called the ECOG score of 0–2) - People with a thyroid nodule measuring between 11 and 40 mm, as seen on ultrasound, where a needle biopsy o...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06087068 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 July 2026
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 to 70 years old who are in reasonably good general health (as measured by a performance scale called ECOG, scored 0–2) - People who have a thyroid nodule on one side of the thyroid only, measuring no more than 4.0 cm across, confirmed by ultrasound - People wh...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06133374 · University of Calgary Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 May 2028
🇨🇦 CA

Who might be able to join this trial: - You are 18 years of age or older - You have been diagnosed with papillary thyroid cancer based on a needle biopsy result that came back as a high-suspicion or likely cancerous result (called Bethesda V or VI) - You have an unclear or uncertain thyroid nodule biopsy result (called...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06141369 · Shanghai Jiao Tong University School of Medicine Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 December 2026
🇨🇳 CN

Who might be able to join this trial: - People who are willing to sign a consent form and are able to attend the required visits and follow the study procedures - People who are 18 years old or older, of any gender - People who have been diagnosed with advanced endocrine tumours (such as medullary thyroid cancer, thymi...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06146764 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 June 2026
🇨🇳 CN

Who might be able to join this trial: - You have one or more thyroid nodules that are at least partly solid and measure 5mm or larger, confirmed by a standard ultrasound scan - You have already had a standard ultrasound, a contrast-enhanced ultrasound (an ultrasound using a special dye to show more detail), and a fine-...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06149637 · Centro de Excelencia en Enfermedades de Cabeza y Cuello Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 August 2025
🇨🇴 CO

**Who might be able to join this trial:** - You are 18 years old or older - You have lymph nodes in the side of your neck that appear to be affected by cancer, based on a physical exam, scans, or findings during surgery - A needle biopsy of your lymph nodes has shown signs of, or confirmed, a type of thyroid cancer cal...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06158360 · Ilsan Cha hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2029
🇰🇷 KR

**Who might be able to join this trial:** - You are 19 years of age or older - You have been confirmed to have a malignant (cancerous) tumor of the thyroid gland, either through a biopsy or imaging scan - You have had part or all of your thyroid gland surgically removed within the last 1 month - You are willing to rece...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06195228 · Fudan University Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 31 December 2026
🇨🇳 CN

**Who might be able to join this trial:** - You are willing to take part and have signed a consent form agreeing to participate - You are within the age range accepted at the participating clinic (regardless of gender) - You have been diagnosed with locally advanced, recurrent, or spread (metastatic) thyroid cancer tha...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT06207188 · Mayo Clinic Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇺🇸 US

Who might be able to join this trial: - Males and females aged 8 and older who are suspected of having thyroid cancer - People who have swollen or detectable lymph nodes or lumps in the neck that are not part of the thyroid, and who have been referred to Radiology or Endocrinology for a needle biopsy procedure - People...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06220656 · Dartmouth-Hitchcock Medical Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
🇺🇸 US

**Who might be able to join this trial:** - People who are 18 years of age or older. - People who are able and willing to give informed consent, or who have a designated person (such as a family member or legal representative) who can give consent on their behalf. - People whose thyroid nodule is not causing symptoms...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06222606 · Aarhus University Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2027
🇩🇰 DK

**Who might be able to join this trial:** - You are over 18 years old and able to give your own consent to take part. - You have a suspected or confirmed diagnosis of thyroid cancer. - You are scheduled to have your entire thyroid gland removed, or to have a second surgery to remove the remaining thyroid tissue. - Your...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06225765 · Tseung Kwan O Hospital, Hong Kong Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 June 2026
Hong Kong

Who might be able to join this trial: - You have a non-cancerous (benign) thyroid nodule that is smaller than 4cm - You have a thyroid nodule that is suspected to be cancerous, is smaller than 2cm, and is considered suitable for a type of keyhole surgery performed through the mouth Who may not be able to join: - You a...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06235216 · Grupo Espanol de Tumores Neuroendocrinos Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 December 2027
🇪🇸 ES

**Who might be able to join this trial:** - You have given written consent approved by an ethics committee - You are 18 years of age or older - You have been confirmed by tissue testing to have either: advanced or spreading differentiated thyroid cancer that no longer responds to radioactive iodine treatment (Group A)...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06236373 · University of Modena and Reggio Emilia Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 February 2025
🇮🇹 IT

**Who might be able to join this trial:** - You are 18 years old or older - You have had breast, prostate, thyroid, colorectal, multiple myeloma, or lymphoma cancer in the past few years, have finished the main phase of treatment, and are now in a monitoring or maintenance phase - You are a carer or family member suppo...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06239194 · ModeX Therapeutics, An OPKO Health Company Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 August 2028
🇺🇸 US

**Who might be able to join this trial:** - You must be 18 years of age or older - Your cancer must be a solid tumor that has spread to other parts of the body, confirmed by a tissue or cell sample test - You must be fairly active and able to care for yourself, with only minor limitations on physical activity (confirm...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06254859 · Fujian Medical University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2025
🇨🇳 CN

**Who might be able to join this trial:** - You are between 20 and 60 years old - You are scheduled to have a planned surgery to remove one lobe of your thyroid gland, along with the middle section (isthmus) and nearby lymph nodes in the central area of the neck **Who may not be able to join:** - You have had any prev...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06277180 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2025
🇨🇳 CN

**Who might be able to join this trial:** - People aged between 18 and 75 years old - People who have been diagnosed with medullary thyroid cancer (a type of thyroid cancer) and whose doctors have assessed them as suitable for surgery — this includes both newly diagnosed cases and those who have had previous treatment...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06286631 · Second Affiliated Hospital of Xi'an Jiaotong University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 October 2025
🇨🇳 CN

Who might be able to join this trial: - You have been diagnosed with papillary thyroid cancer - You are awake, alert, and able to have a normal conversation - You are between 16 and 80 years old Who may not be able to join: - Your test results (either before or after surgery) show a different type of thyroid tumor, su...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06316895 · Chinese PLA General Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 April 2027
🇨🇳 CN

Who might be able to join this trial: - Adults between 18 and 80 years old, of any sex - People who have been diagnosed with a specific type of thyroid cancer called papillary thyroid carcinoma, confirmed by a biopsy procedure - People whose thyroid tumour measures 2.0 cm or smaller at its widest point - People whose s...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06333587 · European Institute of Oncology Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2025
🇮🇹 IT

**Who might be able to join this trial:** - You must be over 18 years old - You must have been diagnosed with a small type of thyroid cancer called papillary thyroid microcarcinoma, confirmed by a cell sample test, and be suitable for a minimally invasive thermal treatment (MITT) - You must be willing and able to sign...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06340945 · Chinese PLA General Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2027
🇨🇳 CN

**Who might be able to join this trial:** - Your thyroid nodule has been confirmed as non-cancerous (benign) by two separate needle biopsy tests - Your thyroid nodule does not show any worrying signs of cancer on an ultrasound scan - You are experiencing cosmetic concerns, symptoms, rapid nodule growth, or worry about...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06356272 · Mayo Clinic Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 November 2029
🇺🇸 US

**Who might be able to join this trial:** - You must be 18 years of age or older - You must be able to sign a written consent form - You must be willing to allow your tumor, tissue, blood, and/or saliva samples to be used for research testing - You must be able to complete questionnaires on your own or with help - You...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06359847 · Beijing Scitech-Mq Pharmaceuticals Limited Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 December 2027
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 years or older - People with a life expectancy of at least 12 weeks - People who have been confirmed through laboratory testing to have locally advanced or metastatic differentiated thyroid cancer (DTC) — including papillary, follicular, Hürthle cell, or poorl...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06374602 · Saint Petersburg State University, Russia Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 25 March 2026
🇷🇺 RU

Who might be able to join this trial: - You have been diagnosed with anaplastic thyroid cancer, confirmed by lab testing of a tissue sample, and surgery to fully remove the cancer is not possible - You are 18 years of age or older - You are reasonably active and able to care for yourself in daily life (this is measured...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06398795 · First Affiliated Hospital of Wenzhou Medical University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇨🇳 CN

Who might be able to join this trial: - You have been diagnosed with thyroid cancer or a non-cancerous (benign) thyroid tumor - You are interested in improving the appearance of a surgical scar Who may not be able to join: - Your thyroid cancer tumor is larger than 2 cm (about the size of a small grape) - Your non-can...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06405217 · Nanjing First Hospital, Nanjing Medical University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 March 2026
🇨🇳 CN

**Who might be able to join this trial:** - You are between 18 and 75 years old (inclusive) - You are reasonably active and able to care for yourself, with only limited physical restrictions (confirm with trial site) - Your doctors expect you to live for more than 3 months - You have been diagnosed with differentiated...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06421805 · Peking Union Medical College Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 December 2044
🇨🇳 CN

Who might be able to join this trial: - You have been diagnosed with a tumor in the mediastinum (the area in the chest between the lungs) either through clinical assessment or laboratory/tissue testing. - You are able and willing to provide written consent to participate in the study. Who may not be able to join: - Yo...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06423235 · Xintian Pharmaceutical Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 30 July 2025
🇨🇳 CN

**Who might be able to join this trial:** - You are between 18 and 65 years old - An ultrasound has found one or more thyroid nodules, where the main nodule is solid, measures between 1cm and 3cm, and is classified as C-TIRADS category 3 or 4A (a low-to-mildly suspicious rating on ultrasound) - If there are multiple n...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT06426563 · The University of Hong Kong Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2027
Hong Kong

**Who might be able to join this trial:** - You are 18 years old or older - You have a thyroid nodule that is at least 2cm at its widest point, but with an overall volume smaller than 20ml - Your nodule is made up of mostly solid tissue (at least 80% solid, rather than fluid-filled) - Your nodule has been confirmed as...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06431620 · Nanjing First Hospital, Nanjing Medical University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 May 2026
🇨🇳 CN

**Who might be able to join this trial:** - You are between 18 and 75 years old (including those ages exactly) - You are able to carry out some or all of your normal daily activities (your doctor can confirm this based on your general health score) - You are expected to live for more than 3 months - You have been diag...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06440850 · City of Hope Medical Center Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 22 November 2026
🇺🇸 US

**Who might be able to join this trial:** - People who have given their written agreement to take part, either personally or through an authorised representative - People who are willing to be followed up for approximately 14 months - People aged 18 years or older at the time of giving consent - People who have been d...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06443866 · Miami Cancer Research Center, Inc. Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 January 2029
🇺🇸 US

**Who might be able to join this trial:** - You have had your entire thyroid removed and have been diagnosed with thyroid cancer (any type or stage), and doctors need to check if any cancer remains or has spread - You have known or suspected thyroid cancer that has come back or spread, found through scans (such as ult...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06455371 · University Hospital of North Norway Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
🇳🇴 NO

Who might be able to join this trial: - You have had your entire thyroid gland removed (a procedure called total or completion thyroidectomy) at a hospital in Norway - The reason for your surgery was either a type of thyroid cancer called differentiated thyroid cancer, or non-cancerous (benign) thyroid nodules Who may...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06458036 · Children's Hospital of Philadelphia Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 November 2030
🇺🇸 US

**Who might be able to join this trial:** - You are between 2 and 25 years old (inclusive) - You have been diagnosed with differentiated thyroid cancer, have had your thyroid removed, and have received appropriate treatment for any cancer spread to the lymph nodes in the neck - You have lung nodules (small spots on th...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06463756 · First Affiliated Hospital of Chongqing Medical University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 13 September 2024
🇨🇳 CN

Who might be able to join this trial: - Complete clinical records are available for the person. - The person has been diagnosed with laryngeal squamous cell carcinoma (a type of throat cancer) confirmed through surgery or a biopsy. - A CT scan was performed within 2 weeks before the person's surgery. Who may not be ab...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06475989 · ECOG-ACRIN Cancer Research Group Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 30 September 2030
🇺🇸 US

**Who might be able to join this trial:** - People who are 18 years of age or older. - People whose general health and ability to carry out daily activities falls within an acceptable range, as measured by a standard medical scoring system called ECOG (scores 0, 1, or 2 — meaning fully active to capable of limited sel...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06482086 · West China Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 December 2024
🇨🇳 CN

**Who might be able to join this trial:** - You are an adult who has been newly diagnosed with locally advanced thyroid cancer, or whose thyroid cancer has come back or not gone away, including cancer that has spread to lymph nodes in the neck. - Your thyroid cancer is one of these types: papillary, follicular, medull...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06498674 · Fujian Medical University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 June 2025
🇨🇳 CN

Who might be able to join this trial: - People who have been confirmed through a tissue sample (biopsy) to have a cancerous thyroid tumour and are having surgery to treat it. - People who have a non-cancerous thyroid growth, such as a thyroid adenoma that is causing symptoms like pressure or difficulty swallowing, and...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06507878 · M.D. Anderson Cancer Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 July 2032
🇺🇸 US

**Who might be able to join this trial:** - Adults aged 18 or older (or 21 or older in some countries, such as Singapore) who have been diagnosed with anaplastic thyroid cancer or poorly differentiated thyroid cancer, based on clinical assessment and/or examination of tumor tissue. **Who may not be able to join:** - P...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06520319 · First Affiliated Hospital of Fujian Medical University Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 December 2024
🇨🇳 CN

Who might be able to join this trial: - Adults aged 18 to 80 years old, of any gender - People who have been diagnosed with medullary thyroid cancer (a type of thyroid cancer), confirmed through laboratory testing of tissue samples - People whose medullary thyroid cancer has come back after previous treatment - People...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06523582 · Universidad Nacional Autonoma de Mexico Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 March 2037
🇲🇽 MX

**Who might be able to join this trial:** - Adults (18 years or older) who have been diagnosed — either recently or in the past — with a type of tumour called a neuroendocrine neoplasm (NEN), which can appear in organs such as the lungs, gut, pancreas, thyroid, adrenal glands, or pituitary gland. - People with a diagn...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06524167 · Fudan University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 June 2031
🇨🇳 CN

**Who might be able to join this trial:** - You are willing to take part and are happy to sign a consent form - You are aged 14 or older but under 80 years old (any gender) - You have been diagnosed with thyroid cancer confirmed by a tissue sample test, including types such as differentiated thyroid cancer, medullary c...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06530316 · Fudan University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇨🇳 CN

**Who might be able to join this trial:** - You are willing to take part and have signed a consent form agreeing to join the study - You are 14 years old or older (any gender) - You have been diagnosed with locally advanced thyroid cancer confirmed by a tissue sample test, which may include papillary, medullary, folli...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06539702 · Saglik Bilimleri Universitesi Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 6 August 2024
Turkey (Türkiye)

Who might be able to join this trial: - You are between 18 and 75 years old - You have received a "Bethesda III" result from a needle biopsy of your thyroid (a type of unclear or uncertain biopsy result) and have decided to have thyroid surgery Who may not be able to join: - You are outside the age range of 18 to 75 y...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06554652 · Fudan University Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 30 June 2029
🇨🇳 CN

**Who might be able to join this trial:** - People who have been diagnosed with papillary thyroid cancer (a specific type of thyroid cancer), confirmed by laboratory testing of tissue samples - People between the ages of 14 and 80 - People whose lymph node biopsy (a procedure using a thin needle) before surgery has co...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06558981 · Fudan University Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 June 2031
🇨🇳 CN

**Who might be able to join this trial:** - People who have voluntarily agreed to take part and have signed a consent form - People aged 14 years or older and under 80 years old, of any gender - People who have been diagnosed with differentiated thyroid cancer confirmed by a tissue biopsy - People who have had their e...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06592755 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 September 2024
🇨🇳 CN

Who might be able to join this trial: - People with a thyroid tumour that is smaller than 3.0 cm in size - People diagnosed with a type of thyroid cancer called well-differentiated papillary thyroid carcinoma, which is a specific slow-growing form of the disease Who may not be able to join: - People whose ultrasound s...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06610604 · Ming-an Yu Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2027
🇨🇳 CN

Who might be able to join this trial: - You have been diagnosed with either a non-cancerous (benign) thyroid nodule or a type of thyroid cancer called papillary thyroid carcinoma - You have had one of two procedures: microwave ablation (a treatment using heat to destroy tissue) or surgical removal of part or all of the...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06623500 · Shandong Provincial Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
🇨🇳 CN

**Who might be able to join this trial:** - You are between 18 and 65 years old (any gender) - You have lived in the study's selected area for at least 5 years - You have had thyroid surgery at one of the research centres and were confirmed to have thyroid cancer through a laboratory tissue test - Your medical records...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06623578 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2033
🇨🇳 CN

**Who might be able to join this trial:** - You are between 18 and 70 years old (male or female) - You have been diagnosed with a type of thyroid cancer called papillary thyroid carcinoma, and a needle biopsy has confirmed that cancer has spread to lymph nodes on the same side of the neck - Your thyroid tumor is smalle...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06627998 · IRCCS San Raffaele Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2024
🇮🇹 IT

Who might be able to join this trial: - You are 18 years old or older - You have been diagnosed with thyroid cancer, confirmed by a tissue sample (biopsy) - You have chest X-ray images taken from the side (lateral view) as part of your pre-surgery assessment, which can be used to measure the shape of your vertebrae (sp...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06632860 · Peking Union Medical College Hospital Early Phase 1 · 1 country Recruiting
Recruiting Early Phase 1 Est. completion 20 December 2025
🇨🇳 CN

Who might be able to join this trial: - People who have been diagnosed with cancer that has been confirmed through laboratory testing of tissue samples - People who are able to have two specific types of medical scans (68Ga-TATE-RGD and 18F-FDG PET/CT) within the same week - People who have given their written agreemen...

Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.
NCT06639191 · Karolinska University Hospital Early Phase 1 · 1 country Recruiting
Recruiting Early Phase 1 Est. completion 1 November 2027
🇸🇪 SE

**Who might be able to join this trial:** - People aged 18 or older who are willing and able to sign a written consent form - People who have a solid tumour cancer that has spread or cannot be surgically removed, has tested positive for a protein called CD44v6, and has continued to grow or spread within the last 8 wee...

Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.
NCT06671184 · Shanghai 6th People's Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2027
🇨🇳 CN

Who might be able to join this trial: - People who have been diagnosed with differentiated thyroid cancer where the tumour measures no more than 4 cm across - People who do not have signs of cancer spread to the lymph nodes on the sides of the neck or to other parts of the body - People who have strong concerns about t...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06673329 · Brian Henick, MD Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 May 2027
🇺🇸 US

**Who might be able to join this trial:** - People who are able to give written consent themselves, or have a guardian who can do so on their behalf - People who are over 18 years of age - People who have been diagnosed with a side effect from immunotherapy treatment that is clinically suspected to be caused by a spec...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06725576 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 4 March 2025
🇨🇳 CN

**Who might be able to join this trial:** - You have been diagnosed with papillary thyroid cancer (a specific type of thyroid cancer), confirmed by a needle biopsy test - Genetic testing done before surgery showed that your cancer has a "low-risk" gene mutation type - You do not have any serious conditions such as hea...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06729762 · Chinese PLA General Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2028
🇨🇳 CN

**Who might be able to join this trial:** - You have had two separate needle biopsies (tissue samples) of a thyroid nodule, and both confirmed it is non-cancerous (benign) - Your thyroid nodule did not show any worrying signs of cancer on an ultrasound scan - You are experiencing cosmetic concerns (such as visible swel...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06730321 · Shanghai 6th People's Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2027
🇨🇳 CN

**Who might be able to join this trial:** - People who have been clinically diagnosed with differentiated thyroid cancer where the tumour is no larger than 4 cm across - People who have been clinically diagnosed with a non-cancerous (benign) thyroid nodule that is no larger than 6 cm across - People who have strong con...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06730529 · Ruijin Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2029
🇨🇳 CN

Who might be able to join this trial: - You have been diagnosed with thyroid cancer that has spread to the lymph nodes (confirmed by medical tests and tissue samples). - You are willing and able to sign and date a consent form agreeing to take part in the study. - You are willing to follow all study procedures and take...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06733740 · Chinese PLA General Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2028
🇨🇳 CN

Who might be able to join this trial: - People between 18 and 80 years old, of any sex - People who have been diagnosed with a specific type of thyroid cancer called papillary thyroid carcinoma, confirmed through a needle biopsy or fine needle sample - People whose thyroid tumour measures 2.0 cm (about the size of a sm...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06733753 · Chinese PLA General Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2028
🇨🇳 CN

**Who might be able to join this trial:** - You have had a needle biopsy of your thyroid that came back with an uncertain result (classified as "Bethesda III or IV"), and a specific genetic test (BRAF V600E) came back negative - Scans and imaging (ultrasound and CT scans of the neck and chest) show no signs that the th...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06733766 · Chinese PLA General Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2028
🇨🇳 CN

**Who might be able to join this trial:** - You have had surgery to remove your thyroid gland due to thyroid cancer. - A biopsy (tissue sample) has confirmed that your cancer has come back in the same area. - There is no sign that the cancer has spread to distant parts of your body. - You have been monitored and follow...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06736015 · Regina Elena Cancer Institute Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 March 2026
🇮🇹 IT

Who might be able to join this trial: - You must be an adult aged 18 or older - Both men and women are welcome to participate - You must have thyroid nodules that were classified as "TIR 3A" (a specific category of uncertain or mildly abnormal results) based on a needle biopsy test (called a fine needle aspiration) - Y...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06738888 · Shanghai 6th People's Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2027
🇨🇳 CN

Who might be able to join this trial: - You have been diagnosed with a type of thyroid cancer called differentiated thyroid cancer, and the tumour is no larger than 4 cm - You have been diagnosed with a non-cancerous (benign) thyroid nodule that is no larger than 6 cm - There are no signs that the cancer has spread to...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06752239 · Jiangxi Provincial Cancer Hospital Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 31 December 2030
🇨🇳 CN

**Who might be able to join this trial:** - You are between 18 and 70 years old (male or female) - You have been diagnosed with nasopharyngeal carcinoma (a type of cancer in the back of the nose/throat) confirmed by a tissue test - Certain lymph nodes in specific areas of your neck (regions III and IVa) do not show si...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06779747 · IRCCS Azienda Ospedaliero-Universitaria di Bologna Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 29 December 2041
🇮🇹 IT

Who might be able to join this trial: - You must be 18 years old or older at the time you were diagnosed - You must have been diagnosed with a thyroid condition, which could include an underactive thyroid, overactive thyroid, a non-cancerous thyroid lump, or thyroid cancer — whether diagnosed at this centre or another...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06787911 · Yu Wang Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 May 2025
🇨🇳 CN

**Who might be able to join this trial:** - People who are willing to take part and have signed a written consent form - People aged 18 to 80 years old, of any gender - People who have been diagnosed with locally advanced differentiated thyroid cancer (a specific type of thyroid cancer confirmed by a tissue sample) -...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06791005 · Second Affiliated Hospital of Xi'an Jiaotong University Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 30 June 2025
🇨🇳 CN

**Who might be able to join this trial:** - People whose thyroid cancer was identified before surgery as being smaller than 4 cm in size. - People whose post-surgery tissue analysis confirmed that cancer was present in both sides of the thyroid, or that cancer had spread to lymph nodes in the side of the neck. - People...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06800482 · West China Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 7 August 2026
🇨🇳 CN

Who might be able to join this trial: - People who have been clinically diagnosed with papillary thyroid cancer - People who have already had thyroid surgery (either open surgery or endoscopic/keyhole surgery) - People aged between 18 and 90 years old - People who speak Chinese - People who are able to use a mobile pho...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06800768 · Ruijin Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 January 2030
🇨🇳 CN

Who might be able to join this trial: - You have been diagnosed with thyroid cancer, have had surgery, and doctors currently suspect the cancer may have come back or spread to other parts of the body. - You are willing and able to sign and date a consent form agreeing to take part. - You are willing to follow all the s...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06814496 · University of Arizona Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 May 2030
🇺🇸 US

**Who might be able to join this trial:** - Adults aged 18 or older who have given their written agreement to take part before any study procedures begin. - People with a confirmed diagnosis of small cell lung cancer (SCLC), another cancer with similar small cell features, a high-grade or poorly differentiated neuroen...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06835426 · Algemeen Ziekenhuis Maria Middelares Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 January 2027
🇧🇪 BE

**Who might be able to join this trial:** - You are able to understand what the study involves and can agree to take part in writing - The study team believes you are likely to follow the study requirements - You have confirmed or suspected breast cancer and are scheduled for surgery that removes part of the breast -...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06840106 · Ilsan Cha hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2027
🇰🇷 KR

Who might be able to join this trial: - You are between 19 and 69 years old - You had your thyroid gland surgically removed because of a thyroid tumor, and a breathing tube was used during the operation - You were considered generally healthy or had only mild health conditions before surgery (rated as ASA I or II — con...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06849284 · Royal Cornwall Hospitals Trust Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 June 2025
🇬🇧 GB

Who might be able to join this trial: - People who have a thyroid nodule (a lump in the thyroid gland) that is at least 1.0 cm in size - People whose thyroid nodule biopsy results came back unclear or uncertain (not definitively normal or cancerous) - People who are already scheduled to have surgery related to their th...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06851663 · RenJi Hospital Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 December 2027
🇨🇳 CN

Who might be able to join this trial: - You are between 18 and 75 years old (any sex) - You have been diagnosed with a solid tumour confirmed by a tissue biopsy, OR imaging scans suggest you may have a solid tumour — the types of cancer include bladder cancer, prostate cancer, lung cancer, nasopharyngeal (nose/throat)...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06853925 · Georgetown University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 February 2027
🇺🇸 US

Who might be able to join this trial: - People aged 18 or older who have been diagnosed with differentiated thyroid cancer (either papillary or follicular type) - People who received radioactive iodine (RAI) treatment within the last three years - People experiencing mild to moderate side effects from radioactive iodin...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06855680 · Royal Marsden NHS Foundation Trust Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 October 2025
🇬🇧 GB

**Who might be able to join this trial:** - People aged 18 or older - People of any gender - People diagnosed with a low-risk, slow-growing type of thyroid cancer (called papillary or follicular thyroid carcinoma) where the tumour measures between 1 and 4 centimetres — diagnosed either by a needle biopsy test before s...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06860971 · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 January 2027
🇨🇳 CN

Who might be able to join this trial: - People who are willing to take part voluntarily, sign a consent form, and are able to follow the study requirements. - People who have been confirmed through a tissue or cell sample to have locally advanced or metastatic differentiated thyroid cancer. - People aged 18 to 74 years...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06863805 · IRCCS Azienda Ospedaliero-Universitaria di Bologna Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇮🇹 IT

**Who might be able to join this trial:** - You must be willing and able to sign a consent form agreeing to take part in the study - You must be an adult aged 18 or older (male or female) - You must have been diagnosed with advanced thyroid cancer, confirmed by a central review of tissue samples - Your thyroid cancer m...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06878534 · IRCCS SYNLAB SDN Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 July 2024
🇮🇹 IT

**Who might be able to join this trial:** - You are over 18 years old (any gender) and have been diagnosed with a type of thyroid cancer that originates from follicular cells (a specific cell type in the thyroid gland) **Who may not be able to join:** - Anyone who does not meet the inclusion criteria listed above **I...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06898437 · Peking Union Medical College Hospital Early Phase 1 · 1 country Recruiting
Recruiting Early Phase 1 Est. completion 23 March 2026
🇨🇳 CN

**Who might be able to join this trial:** - You are 18 years of age or older - You have been diagnosed with a type of thyroid cancer (differentiated thyroid cancer) that no longer responds to radioactive iodine treatment, and either previous targeted drug treatments have not worked for you, or you have chosen not to h...

Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.
NCT06902376 · UNC Lineberger Comprehensive Cancer Center Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 31 March 2028
🇺🇸 US

**Who might be able to join this trial:** - You are 18 years old or older at the time of signing the consent form. - You are willing and able to follow the study procedures, as judged by the study doctor. - You are willing to sign a consent form agreeing to take part and allowing your health information to be shared f...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06918223 · Thomas Jefferson University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2025
🇺🇸 US

Who might be able to join this trial: - You speak English fluently and it is your primary language - You are 18 years old or older at the time of signing the consent form - You have been recommended for surgery to remove all or part of your thyroid gland (for any medical reason) Who may not be able to join: - You have...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06923826 · National University Hospital, Singapore Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 April 2030
🇸🇬 SG

**Who might be able to join this trial:** - You (or your legal representative) are willing and able to give written consent to take part. - You are at least 21 years old at the time of signing the consent form. - You have been officially diagnosed (confirmed by lab testing of tissue or cells) with advanced or inoperab...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06929650 · University Health Network, Toronto Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2025
🇨🇦 CA

**Who might be able to join this trial:** - You have a thyroid nodule that is 2cm or smaller in size, and it has been classified as Bethesda category 5 or 6 (meaning cells from a biopsy look likely or confirmed to be cancerous) - You are 18 years of age or older (up to 100 years old) - You are able to sign and provide...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06937112 · Nanjing First Hospital, Nanjing Medical University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 January 2026
🇨🇳 CN

**Who might be able to join this trial:** - You are willing to take part and have signed a consent form (or a legal guardian has signed on your behalf) - You are between 18 and 75 years old (any gender) - A scan (such as a CT or MRI) has shown a tumor or growth in your body - You have been diagnosed with lung cancer,...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06959511 · M.D. Anderson Cancer Center Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 March 2028
🇺🇸 US

**Who might be able to join this trial:** - People diagnosed with differentiated thyroid cancer, medullary thyroid cancer (without a RET gene mutation), or poorly differentiated thyroid cancer, where the cancer has spread beyond the thyroid into nearby tissue or lymph nodes, or has come back or left significant diseas...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06959641 · Jochen Lorch Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 11 September 2028
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with locally advanced or metastatic differentiated thyroid cancer (including papillary, follicular, oncocytic/Hürthle cell, or poorly differentiated types) that has been confirmed by a tissue biopsy, has stopped responding to radioactive iodine...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06961084 · Thomas Hope Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 April 2028
🇺🇸 US

Who might be able to join this trial: - People aged 13 years or older. - People who have been diagnosed with differentiated or poorly differentiated thyroid cancer, confirmed by laboratory tissue testing. - People who fall into one of two groups: those with intermediate or high-risk thyroid cancer (as classified by the...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06970353 · Fudan University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 December 2026
🇨🇳 CN

**Who might be able to join this trial:** - People who have voluntarily agreed to take part and have signed a consent form - Adults aged 18 or older, of any gender - People who have been diagnosed by tissue testing (biopsy) with locally advanced or returned/spread thyroid cancer that cannot be removed with surgery, an...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06980103 · Georgetown University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 28 February 2029
🇺🇸 US

Who might be able to join this trial: - Adults aged 18 or older - People who have been diagnosed with intermediate risk differentiated thyroid cancer (a specific type of thyroid cancer) within the last 6 months and are currently deciding whether to have radioactive iodine treatment - People who are able to understand t...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06984991 · Assiut University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 July 2026
🇪🇬 EG

**Who might be able to join this trial:** - People who have been referred for a needle biopsy (called a fine needle aspiration, or FNA) of a thyroid nodule, where the nodule has been rated as a category 3, 4, or 5 on a standard thyroid risk scoring system (TI-RADS) **Who may not be able to join:** - People who have pr...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07010380 · Bo Wang,MD Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2027
🇨🇳 CN

Who might be able to join this trial: - People who are 18 years of age or older - People who have a planned (non-emergency) surgery to remove all or part of the thyroid gland, or to remove one or more parathyroid glands - People who are willing and able to sign a written consent form agreeing to take part and to have t...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07016230 · Gustave Roussy, Cancer Campus, Grand Paris Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 15 April 2027
🇫🇷 FR

**Who might be able to join this trial:** - People aged 18 or older - People with a confirmed diagnosis of small cell lung cancer (SCLC) that has spread or cannot be surgically removed, regardless of DLL3 protein levels in the tumour (this applies to one group in the trial) - People with certain other poorly different...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07033572 · Fujian Medical University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 June 2026
🇨🇳 CN

Who might be able to join this trial: - Adults between 18 and 65 years old - People who have a small thyroid cancer (no larger than 1.5 cm) on the dominant side of the thyroid that is suitable for removal using an endoscopic (camera-guided) procedure - People who have a small nodule (no larger than 7 mm) on the opposit...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07041307 · Rigshospitalet, Denmark Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2028
🇩🇰 DK

Who might be able to join this trial: - You are 18 years of age or older - You are willing and able to give your agreement to take part in the study, both in writing and verbally - You have a thyroid nodule that is overactive, underactive, or functioning normally - You have been referred for thyroid surgery because a n...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07046546 · Royal Berkshire NHS Foundation Trust Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 November 2026
🇬🇧 GB

The eligibility criteria provided appear to contain a formatting error — the exclusion criteria section repeats the inclusion criteria rather than listing separate exclusion criteria. I will convert what has been provided accurately, and flag where exclusion criteria should be confirmed directly with the trial site. -...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07059507 · Minia University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 15 July 2026
🇪🇬 EG

**Who might be able to join this trial:** - You are 18 years old or older - You have been diagnosed with Graves' disease, confirmed through symptoms (such as an enlarged thyroid or eye problems) and blood tests showing abnormal thyroid hormone levels and/or a positive antibody test - You have a medical reason to have y...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07068542 · Zhejiang Provincial People's Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2027
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 or older at the time of signing the consent form. - People who have been diagnosed through a tissue biopsy with one of the following advanced thyroid cancers that cannot be surgically removed, has spread locally, or has spread to other parts of the body: anapl...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07092514 · Washington University School of Medicine Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 17 April 2029
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with a specific type of thyroid cancer (called differentiated thyroid cancer, or DTC) — including papillary, follicular, or Hürthle cell thyroid cancer — confirmed by a tissue sample test. - Your cancer cannot be cured and has stopped responding to ra...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07102264 · Insel Gruppe AG, University Hospital Bern Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 16 December 2026
🇨🇭 CH

Who might be able to join this trial: - You must be older than 18 years of age - You have a growth or lump on your thyroid gland (a small gland in your neck) - A biopsy of this lump has come back with a specific result called "Bethesda IV," which means the cells looked slightly abnormal but it is unclear if they are ca...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07124000 · AstraZeneca Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 March 2028
🇺🇸 US

**Who might be able to join this trial:** - You are 18 years of age or older - You have a solid tumor (cancer) that has spread or cannot be surgically removed, and your cancer has tested positive for a protein called HER2 (at a level called IHC 3+) based on local lab testing before joining the study - You have already...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07138716 · Luo Yaping Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2027
🇨🇳 CN

**Who might be able to join this trial:** - People of any age, whether male or female, may be considered - People who have been diagnosed with, or are suspected to have, a type of thyroid cancer called medullary thyroid carcinoma (MTC) — confirmed through a biopsy, elevated blood markers alongside a thyroid nodule, or...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07140757 · M.D. Anderson Cancer Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2028
🇺🇸 US

**Who might be able to join this trial:** - People who are scheduled to have a procedure called radiofrequency ablation (RFA) — a heat-based treatment guided by ultrasound — for a thyroid condition - People who are over 18 years old and are either not suitable for surgery or have chosen not to have surgery - People wh...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07142005 · M.D. Anderson Cancer Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 March 2026
🇺🇸 US

**Who might be able to join this trial:** - People who have signed and dated a consent form agreeing to take part - Adults aged 18 or older - People who identify their ethnicity as Hispanic or Latino/Latina - People who are able to read, write, and speak Spanish - People who are pregnant are still eligible to participa...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07181720 · Chongqing Precision Biotech Co., Ltd Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 31 March 2028
🇨🇳 CN

**Who might be able to join this trial:** - You are 18 years old or older - You have been diagnosed with an advanced or metastatic solid tumor (a cancer that has spread), and lab testing has confirmed that your tumor strongly expresses a protein called CD70 (shown by a specific lab score called IHC 3+) - Your cancer h...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07218315 · M.D. Anderson Cancer Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 January 2029
🇺🇸 US

**Who might be able to join this trial:** - You must be willing to give written consent to take part in the study voluntarily. - You must agree to follow all study steps, including attending all follow-up appointments. - You have a thyroid nodule that has been tested and placed in a category called "Bethesda VI," the n...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07225309 · Memorial Sloan Kettering Cancer Center Not Applicable · 2 countries Recruiting
Recruiting Not Applicable Est. completion 13 April 2029
🇲🇽 MX🇺🇸 US

**Patient Eligibility** Who might be able to join this trial: - People who have been diagnosed with breast, prostate, colorectal, thyroid, cervical, uterine, or lung cancer (solid tumour), confirmed by a pathology report, either as a new or existing diagnosis - People whose cancer is at stage III or IV - People who ar...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07226804 · M.D. Anderson Cancer Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 August 2028
🇺🇸 US

**Who might be able to join this trial:** - You are already scheduled to have a specific thyroid treatment procedure (called nsPFA) guided by ultrasound as part of your normal care - You are between 18 and 80 years old - You are able to give your own consent to take part without assistance - You have a thyroid nodule...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07235566 · Fudan University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 April 2029
🇨🇳 CN

Who might be able to join this trial: - Adults aged 18 or older who are willing to sign a consent form and follow the study's requirements. - People with a life expectancy of at least 12 weeks. - People who have been diagnosed through laboratory testing with a specific type of thyroid cancer called anaplastic thyroid c...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07244835 · Degron Therapeutics Co. Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 December 2028
🇨🇳 CN

Who might be able to join this trial: - You are willing and able to sign a consent form agreeing to take part in the study - You are 18 years of age or older - If you are a woman who could become pregnant, you must agree to use highly effective birth control during the study and for 30 days after your last dose, and mu...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07259304 · University of Southern California Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇺🇸 US

**Who might be able to join this trial:** - You were diagnosed with and/or treated for cancer between the ages of 18 and 39 at USC hospitals - Your cancer is one of the types commonly seen in teenagers and young adults, and is at stage I, II, or III (some stage IV patients may also qualify with special approval — confi...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07270237 · Memorial Sloan Kettering Cancer Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 November 2027
🇺🇸 US

**Who might be able to join this trial:** *This trial has several different groups (cohorts). You may qualify for one of the following:* **Group 1 – People at high risk for pancreatic cancer (having a routine surveillance ultrasound):** - You are already enrolled in the Memorial Sloan Kettering Pancreatic Registry pr...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07287176 · Pulse Biosciences, Inc. Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 June 2026
🇺🇸 US

**Who might be able to join this trial:** - You are willing and able to give your written agreement to take part in the study - You are willing and able to attend all study appointments, including follow-up visits - Your thyroid nodule can be reached using a specific treatment approach through the middle part of the t...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07287748 · Alpha Fusion Inc. Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 31 July 2028
🇯🇵 JP

**Who might be able to join this trial:** - People who have been diagnosed with differentiated thyroid cancer (specifically papillary or follicular type) and have had their entire thyroid surgically removed - People whose cancer cannot be fully removed by surgery, has come back, or has spread to other parts of the bod...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07302672 · Ming-an Yu Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 June 2026
🇨🇳 CN

**Who might be able to join this trial:** - You are between 16 and 60 years old and are scheduled to have a thyroid thermal ablation procedure - You have been diagnosed with a type of thyroid cancer called papillary thyroid carcinoma (PTC) - You have no more than 3 areas in the thyroid that need to be treated - Your la...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07328243 · Tian'an Jiang Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2027
🇨🇳 CN

**Who might be able to join this trial:** - You are willing and able to sign a consent form agreeing to take part in the study. - You are 18 years old or older. - You are generally well enough to carry out light activity or normal daily tasks (your doctor can confirm this based on a standard fitness scale). - Your doc...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07357571 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇨🇳 CN

**Who might be able to join this trial:** - People who were assessed before surgery as having a specific early-stage thyroid cancer (called T1N0M0 papillary thyroid carcinoma) and had their initial surgery at one of the participating medical centres between June 2018 and June 2025. - People whose papillary thyroid car...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07359586 · Zhejiang University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 25 December 2026
🇨🇳 CN

**Who might be able to join this trial:** - You had surgery that required general anesthesia with a breathing tube placed in your throat, at the First Affiliated Hospital of Zhejiang University School of Medicine, between October 2015 and September 2025 - After your surgery, you had throat or voice-related problems (su...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07360587 · Université de Sherbrooke Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2029
🇨🇦 CA

Who might be able to join this trial: - People who have a goitre (enlarged thyroid gland) that is pressing on nearby structures such as the windpipe or food pipe, causing or at risk of causing symptoms - People who are not suitable for surgery or other ablative (tissue-destroying) treatments, or who prefer the procedur...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07370675 · Christian Grønhøj Larsen Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 16 January 2033
🇩🇰 DK

**Who might be able to join this trial:** - You are 30 years of age or older - You have a single thyroid nodule that was found to be a "follicular neoplasm" or "suspicious for a follicular neoplasm" based on a biopsy result (this is called a Category IV result in a standard classification system used by doctors) - The...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07376837 · University Health Network, Toronto Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇨🇦 CA

**Who might be able to join this trial:** - You have been diagnosed with a specific type of thyroid cancer called papillary thyroid carcinoma, confirmed by a needle biopsy or tissue sample. - Your thyroid tumor(s) are each no larger than 2.0 cm (about the size of a small grape) at their widest point. - Your cancer has...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07383246 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 September 2028
🇨🇳 CN

**Who might be able to join this trial:** - You have been newly diagnosed with medullary thyroid carcinoma, confirmed either by a lab test of tissue or cells, OR by a blood test showing a raised calcitonin level (above 10 pg/mL) where other infections or tumour-related causes have been ruled out - Your doctors expect...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07389512 · Hospices Civils de Lyon Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 September 2026
🇫🇷 FR

Who might be able to join this trial: - You are an adult (18 or older) receiving treatment in a nuclear medicine department and have been approved by a pharmacist for your first Targeted Radionuclide Therapy (a type of treatment that uses radioactive substances to target cancer cells). - You are a patient for whom a ph...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07400224 · Peking Union Medical College Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2027
🇨🇳 CN

**Who might be able to join this trial:** - You are 18 years old or older (any gender can apply) - You have had a general health check-up within the last 3 months that included at least a chest X-ray or chest CT scan and an abdominal ultrasound, and no serious health problems were found **Who may not be able to join:*...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07406087 · Kaiser Permanente Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2027
🇺🇸 US

Who might be able to join this trial: - People who were diagnosed with breast, ovarian, cervical, testicular, colon/rectal, melanoma, endometrial, sarcoma, or thyroid cancer when they were between 15 and 39 years old - People who are currently between 21 and 45 years old - People who were diagnosed and treated for thei...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07410637 · University of Ulm Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 February 2031
🇩🇪 DE

Who might be able to join this trial: - You have recently been diagnosed with Graves' disease (an immune system disorder that causes the thyroid to be overactive), OR - You have recently been diagnosed with thyroid cancer Who may not be able to join: - You have a medical reason why you cannot have an oral glucose tole...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07419932 · Fujian Medical University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2028
🇨🇳 CN

**Who might be able to join this trial:** - People who are 14 years of age or older at the time of enrollment - People whose general health and ability to carry out daily activities falls within an acceptable range, as measured by a standard medical scale (ECOG score of 0–2) - People who have been formally diagnosed wi...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07428057 · Minia University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 July 2026
🇪🇬 EG

**Who might be able to join this trial:** - You are 18 years old or older at the time of your thyroid surgery - You had your thyroid removed (thyroidectomy) at Minia University Hospital - Your medical records are available and contain full details about your surgery and recovery - Your blood calcium levels were measure...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07433283 · Sichuan Enray Pharmaceutical Sciences Company Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2026
🇨🇳 CN

**Who might be able to join this trial:** - People who are able to understand and sign a consent form and are willing to follow all trial requirements - Adults between 18 and 80 years old (inclusive) at the time of signing the consent form - People with an advanced solid tumour confirmed by tissue or cell testing, whe...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07436455 · Ankara University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 August 2026
Turkey (Türkiye)

Who might be able to join this trial: - People who have had surgery for a type of thyroid cancer called differentiated thyroid cancer and have also received radioactive iodine treatment - People who are being checked for signs of cancer returning, because their blood tests show elevated levels of certain proteins (call...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07438847 · SHAOYAN LIU Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 31 December 2026
🇨🇳 CN

**Who might be able to join this trial:** - You have been diagnosed with thyroid cancer that has been confirmed by a laboratory test, and if it is a certain type (differentiated thyroid cancer), a specialist has determined it no longer responds to radioactive iodine treatment. - Your cancer has been shown to be growin...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07447089 · Università Cattolica di Milano Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 October 2026
🇮🇹 IT

Who might be able to join this trial: - You have been diagnosed with cancer - You are experiencing significant post-traumatic stress symptoms, as measured by a specific questionnaire score above a certain level (confirm with trial site) Who may not be able to join: - You are currently receiving specialist therapy spec...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07473518 · IRCCS Azienda Ospedaliero-Universitaria di Bologna Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 July 2026
🇮🇹 IT

**Who might be able to join this trial:** *For patients who received radiation therapy for cancer:* - You received radiation therapy (radiotherapy) to treat a cancer condition at some point between January 1, 1999, and December 31, 2018 - You were under 18 years old at the time you received that radiation therapy - Yo...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07488325 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 June 2026
🇨🇳 CN

Who might be able to join this trial: - People who had a needle biopsy of a thyroid nodule and received a specific uncertain result known as a "Bethesda III" diagnosis (meaning the biopsy result was inconclusive or indeterminate). - People who later had thyroid surgery and received a confirmed diagnosis from tissue tes...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07524777 · Ling Zhiqiang Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 July 2026
🇨🇳 CN

**Who might be able to join this trial:** - You are an outpatient at Zhejiang Cancer Hospital who has been diagnosed with papillary thyroid cancer (a specific type of thyroid cancer) confirmed by a tissue test, and you have had surgery for it - You are experiencing symptoms of depression, scored at a certain level on a...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07545837 · Mayo Clinic Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 June 2027
🇺🇸 US

Who might be able to join this trial: - Adults aged 18 or older - People who have been diagnosed with a specific type of thyroid cancer (papillary or follicular thyroid carcinoma), confirmed through laboratory testing of tissue - People who have had their entire thyroid gland surgically removed, with or without follow-...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07591246 · Cairo University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 December 2026
🇪🇬 EG

Who might be able to join this trial: - You have been diagnosed with Polycystic Ovary Syndrome (PCOS), a hormonal condition affecting the ovaries - You have a fatty pancreas that is not caused by alcohol use - Your thyroid is underactive in a mild way, shown by a specific thyroid hormone level (TSH) above 10 mIU/L, whi...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07600580 · University Hospital Dubrava Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 3 February 2027
🇭🇷 HR

**Who might be able to join this trial:** - Both men and women are welcome to participate - You must be 18 years of age or older - You must be generally healthy or have only mild health conditions that are well controlled (confirm with trial site regarding "ASA I or II" classification) - Your thyroid hormone levels mus...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT07634978 · Tianjin Medical University Cancer Institute and Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 August 2026
🇨🇳 CN

Who might be able to join this trial: - People who have been diagnosed with thyroid cancer, confirmed through ultrasound and tissue sample examination. - People who are scheduled to have planned surgery for thyroid cancer. - People who are mentally able to understand the study details and have agreed in writing to take...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07704658 · Rigel Pharmaceuticals Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 30 July 2027
🇪🇸 ES

**Who might be able to join this trial:** - People who are willing and able to follow all study requirements and can give written, signed, and dated consent to participate. - People who are 18 years of age or older at the time of signing the consent form. - People with a body mass index (BMI) between 18 and 32, and wh...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT07707401 · Shanghai 6th People's Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2028
🇨🇳 CN

Who might be able to join this trial: - People who are scheduled to have or have recently had thyroid surgery - People whose recovery after surgery is stable, and whose attending doctor has assessed them as ready to move their neck - People who are willing to take part in the study, attend follow-up appointments as sch...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Advocacy and support in Australia

Organisations that can offer information, support, or connection for Thyroid Cancer. Where more than one is listed, they serve different needs or regions, so choose whichever fits your situation.

Thyroid cancer is also covered by Head and Neck Cancer Australia's national work.

This is a starting point, not medical advice or an endorsement. Contact details change; search the organisation name to find its current website.